Biotech2050 Podcast: Sergey Jakimov on Defining Longevity, Healthspan, and the Investment Gaps in Between
LongeVC managing partner Sergey Jakimov joined Alok Tayi, on the Biotech2050 podcast to discuss the growing distinction between biotech and longevity, and why that difference matters for founders, investors, and regulators alike.
The conversation covers why LongeVC focuses on healthspan rather than lifespan, what traditional medicine overlooks in aging, and how the industry can move beyond optimization tools and platform fatigue. Sergey also shared views on clinical endpoints, partner expectations, and the need for clear entry and exit points in longevity investing.
The discussion touched on early opportunities in categories like pet longevity and what it will take to translate long-term vision into practical, fundable progress.